Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Genus Lifesciences has announced the re-introduction of Yosprala delayed-release tablets to the US market.
Approved in 2016, Yosprala is a combination of aspirin, an antiplatelet agent, and omeprazole, a proton pump inhibitor (PPI); the combination therapy had been discontinued by Aralez Pharmaceuticals in 2018 based on a business decision and not a safety issue.
Yosprala is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers. According to Genus Lifesciences, the product will be available for $33 for a 30-day supply.
“We are confident that with a unique formulation and new price point, Yosprala will help healthcare practitioners treat patients with secondary cardiovascular and cerebrovascular events with decreased risk of aspirin-associated gastric ulcers,” said Jeffrey Moshal, Chief Executive Officer, Genus Lifesciences, Inc.
Yosprala is available in 2 dosage strengths: aspirin 81mg delayed-release/omeprazole 40mg immediate-release tablets and aspirin 325mg delayed-release/omeprazole 40mg immediate-release tablets. It is not interchangeable with the individual components as the proprietary delivery system is designed to sequentially deliver omeprazole and aspirin.
For more information visit yospralahcp.com.
